Triton BioSystems Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Triton BioSystems Inc.
Bristol signs a licensing deal around CytomX’s Probody technology platform and becomes the third firm to set up a combination trial with Incyte’s IDO1 inhibitor. Janssen licenses novel immunotherapy candidates for prostate cancer from Aduro; Oncothyreon and Celldex arrange a combo trial in breast and ovarian cancer.
Nanobiotix is taking advantage of the ability of nanoparticles to absorb and transform energy to treat cancer. The company's nanoXray technology uses standard x-ray to activate injected cell-targeting non-drug nanoparticles. Today, Nanobiotix is focused solely on cancer applications of its technology, but the company believes there are other targets for the technology, including cardiovascular diseases.
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, What Nanotech Means to Health Care Investors, features profiles of Keystone Nano, Mersana Therapeutics, Nanotrope and Triton BioSystems. Plus these Start-Up Across Health Care: Biowave, MediWound, OrthoHelix Surgical Designs and TheraPei Pharmaceuticals.
Triton BioSystems eradicates tumors by using magnetic energy to heat up nano-sized iron oxide-based spheres that have localized in tumor tissue.
- Drug Delivery